Medications

Study to test pneumococcal vaccine in older adults

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

Oncology & Cancer

Single-dose PCV13 immunogenic, safe in pediatric oncology

(HealthDay)—For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published online July 11 in Cancer.

Pediatrics

No increase in febrile seizures with 2010-2011 TIV or PCV13

(HealthDay)—For the 2010-2011 influenza season, there was no increase in the risk of febrile seizures (FS) with the trivalent inactivated influenza vaccine (TIV) or the 13-valent pneumococcal conjugate vaccine (PCV13), ...

Health

Using price to avoid vaccine shortages

No one worries about vaccine supply—until there's a shortage. New research from Duke University's Fuqua School of Business studied the market tensions that can keep manufacturers out of the business and the price points ...

Pediatrics

PCV13 recommended for 6- to 18-year-olds at high risk

(HealthDay)—Pneumococcal conjugate vaccine 13 (PCV13) should be administered to certain children aged 6 through 18 years who are at high risk of invasive pneumococcal disease (IPD), according to a policy statement published ...

Diseases, Conditions, Syndromes

Drop in childhood pneumococcal, Hib deaths from 2000 to 2015

(HealthDay)—Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) deaths in children decreased between 2000 and 2015, following introduction of the pneumococcal conjugate vaccine (PCV) and Hib vaccine, according ...

page 3 from 4